923 related articles for article (PubMed ID: 17612779)
21. Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial.
Van Poznak C; Hannon RA; Mackey JR; Campone M; Apffelstaedt JP; Clack G; Barlow D; Makris A; Eastell R
J Clin Oncol; 2010 Feb; 28(6):967-75. PubMed ID: 20065185
[TBL] [Abstract][Full Text] [Related]
22. [Effect of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis].
Liu JL; Zhu HM; Huang QR; Zhang ZL; Li HL; Qin YJ; Zhang Y; Wei DL; Lu JH; Liu H; Chen XP; Liu YJ; Ekangaki A; Zheng YM; Diez-Perez A; Harpe K
Zhonghua Yi Xue Za Zhi; 2004 Feb; 84(4):269-73. PubMed ID: 15059505
[TBL] [Abstract][Full Text] [Related]
23. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials.
Miller PD; Roux C; Boonen S; Barton IP; Dunlap LE; Burgio DE
J Bone Miner Res; 2005 Dec; 20(12):2105-15. PubMed ID: 16294264
[TBL] [Abstract][Full Text] [Related]
24. Tibolone and osteoporosis.
Lazovic G; Radivojevic U; Milosevic V; Lazovic A; Jeremic K; Glisic A
Arch Gynecol Obstet; 2007 Dec; 276(6):577-81. PubMed ID: 17605023
[TBL] [Abstract][Full Text] [Related]
25. Evidence for safety and efficacy of risedronate in men with osteoporosis over 4 years of treatment: Results from the 2-year, open-label, extension study of a 2-year, randomized, double-blind, placebo-controlled study.
Boonen S; Lorenc RS; Wenderoth D; Stoner KJ; Eusebio R; Orwoll ES
Bone; 2012 Sep; 51(3):383-8. PubMed ID: 22750403
[TBL] [Abstract][Full Text] [Related]
26. Risedronate reduces intracortical porosity in women with osteoporosis.
Borah B; Dufresne T; Nurre J; Phipps R; Chmielewski P; Wagner L; Lundy M; Bouxsein M; Zebaze R; Seeman E
J Bone Miner Res; 2010 Jan; 25(1):41-7. PubMed ID: 19580469
[TBL] [Abstract][Full Text] [Related]
27. Effect of risedronate on osteocyte viability and bone turnover in paired iliac bone biopsies from early postmenopausal women.
Qiu S; Phipps RJ; Ebetino FH; Palnitkar S; Sudhaker Rao D
Calcif Tissue Int; 2010 Nov; 87(5):392-7. PubMed ID: 20809096
[TBL] [Abstract][Full Text] [Related]
28. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.
Boonen S; Marin F; Mellstrom D; Xie L; Desaiah D; Krege JH; Rosen CJ
J Am Geriatr Soc; 2006 May; 54(5):782-9. PubMed ID: 16696744
[TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old.
Boonen S; McClung MR; Eastell R; El-Hajj Fuleihan G; Barton IP; Delmas P
J Am Geriatr Soc; 2004 Nov; 52(11):1832-9. PubMed ID: 15507059
[TBL] [Abstract][Full Text] [Related]
30. Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure.
Recker RR; Delmas PD; Halse J; Reid IR; Boonen S; García-Hernandez PA; Supronik J; Lewiecki EM; Ochoa L; Miller P; Hu H; Mesenbrink P; Hartl F; Gasser J; Eriksen EF
J Bone Miner Res; 2008 Jan; 23(1):6-16. PubMed ID: 17892374
[TBL] [Abstract][Full Text] [Related]
31. Statins have additive effects to vertebral bone mineral density in combination with risedronate in hypercholesterolemic postmenopausal women.
Tanriverdi HA; Barut A; Sarikaya S
Eur J Obstet Gynecol Reprod Biol; 2005 May; 120(1):63-8. PubMed ID: 15866088
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
Sethi BK; Chadha M; Modi KD; Kumar KM; Mehrotra R; Sriram U
J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620
[TBL] [Abstract][Full Text] [Related]
33. Prevention of bone loss and vertebral fractures in patients with chronic epilepsy--antiepileptic drug and osteoporosis prevention trial.
Lazzari AA; Dussault PM; Thakore-James M; Gagnon D; Baker E; Davis SA; Houranieh AM
Epilepsia; 2013 Nov; 54(11):1997-2004. PubMed ID: 24010637
[TBL] [Abstract][Full Text] [Related]
34. Effects of one year daily teriparatide treatment on trabecular bone material properties in postmenopausal osteoporotic women previously treated with alendronate or risedronate.
Gamsjaeger S; Buchinger B; Zoehrer R; Phipps R; Klaushofer K; Paschalis EP
Bone; 2011 Dec; 49(6):1160-5. PubMed ID: 21893225
[TBL] [Abstract][Full Text] [Related]
35. Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis.
Harrington JT; Ste-Marie LG; Brandi ML; Civitelli R; Fardellone P; Grauer A; Barton I; Boonen S
Calcif Tissue Int; 2004 Feb; 74(2):129-35. PubMed ID: 14648009
[TBL] [Abstract][Full Text] [Related]
36. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.
McComsey GA; Kendall MA; Tebas P; Swindells S; Hogg E; Alston-Smith B; Suckow C; Gopalakrishnan G; Benson C; Wohl DA
AIDS; 2007 Nov; 21(18):2473-82. PubMed ID: 18025884
[TBL] [Abstract][Full Text] [Related]
37. The relationship between regional bone turnover measured using 18F-fluoride positron emission tomography and changes in BMD is equivalent to that seen for biochemical markers of bone turnover.
Frost ML; Cook GJ; Blake GM; Marsden PK; Fogelman I
J Clin Densitom; 2007; 10(1):46-54. PubMed ID: 17289526
[TBL] [Abstract][Full Text] [Related]
38. Risedronate decreases bone resorption and improves low back pain in postmenopausal osteoporosis patients without vertebral fractures.
Ohtori S; Akazawa T; Murata Y; Kinoshita T; Yamashita M; Nakagawa K; Inoue G; Nakamura J; Orita S; Ochiai N; Kishida S; Takaso M; Eguchi Y; Yamauchi K; Suzuki M; Aoki Y; Takahashi K
J Clin Neurosci; 2010 Feb; 17(2):209-13. PubMed ID: 20044258
[TBL] [Abstract][Full Text] [Related]
39. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density.
Bone HG; McClung MR; Roux C; Recker RR; Eisman JA; Verbruggen N; Hustad CM; DaSilva C; Santora AC; Ince BA
J Bone Miner Res; 2010 May; 25(5):937-47. PubMed ID: 19874198
[TBL] [Abstract][Full Text] [Related]
40. Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy.
Choo R; Lukka H; Cheung P; Corbett T; Briones-Urbina R; Vieth R; Ehrlich L; Kiss A; Danjoux C
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1239-45. PubMed ID: 23265571
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
